Odronextamab combined with CHOP shows high response rates in high-risk, frontline DLBCL, with manageable safety and low rates of severe immune toxicity. Read More ›

Adding tafasitamab and lenalidomide to R-CHOP improved progression-free survival in patients with high-risk, newly diagnosed DLBCL, with a generally manageable safety profile. Read More ›

Pola-R-CHP shows consistent benefit across DLBCL microenvironment subtypes, with the strongest gains seen in the high-risk FMAC group. Read More ›